Metsera rises after Novo Nordisk and Pfizer sweeten bids

Metsera

04/11/2025 16:55

Updates

** Shares of weight-loss drug developer Metsera MTSR.O rise 19.81% to $72.76

** Novo Nordisk NOVOb.CO and Pfizer PFE.N have revised their bids for Metsera, co says

** Novo's revised offer brings deal value to about $10 billion, while Pfizer is now willing to shell out $8.1 billion

** As per Novo's new offer, Metsera is also eligible to receive additional $24.00 per share in cash, up from $21.25, based on development and regulatory approval milestones

** Pfizer has filed two lawsuits against Metsera, its board and Novo Nordisk

** Including session's moves, MTSR has more than doubled since its stock market debut in January

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com;))